Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Daphne Karydas currently holds 41,000 shares of Mineralys Therapeutics, Inc. (MLYS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Daphne Karydas has been a net seller of MLYS stock. They have purchased $0 and sold $764.8K worth of shares.
Daphne Karydas's most recent insider trade was on Mar 31, 2026, when they sold 3,000 shares at $0.00 per share.
Daphne Karydas serves as Executive at Mineralys Therapeutics, Inc. (MLYS). They have executed 10 insider transactions totaling $764.8K over their tenure at the company.
Daphne Karydas holds the position of Executive at Mineralys Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 2 years and currently hold a stake valued at $0.
Daphne Karydas has shown a selling trading pattern, with $0 in total purchases and $764.8K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Daphne Karydas was on Nov 13, 2025, when they sold $463.4K worth of MLYS shares. This transaction involved 10,115 shares at $45.81 per share.
Daphne Karydas currently owns 41,000 shares of Mineralys Therapeutics, Inc. (MLYS), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Daphne Karydas's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Daphne Karydas has 10 Form 4 filings on record as an insider at Mineralys Therapeutics, Inc..
Set alerts for Daphne Karydas and 40,000+ other insiders.